HONG KONG -- September 01, 2026 -- Fosun International reported a 160.3% year-on-year surge in first-half profit attributable to owners of the parent to RMB1.72 billion, the conglomerate said at an interim results presentation held in Hong Kong on Aug. 28. Total revenue for the six-month period reached RMB86.96 billion, with overseas markets contributing RMB49.16 billion, or 56.5% of the total. The briefing marked Fosun's first in-person results presentation in Hong Kong in six years, attended by Chairman Guo Guangchang, Co-Chairman Wang Qunbin, Co-CEOs Chen Qiyu and Xu Xiaoliang, and CFO Gong Ping.
Four Core Units Generate 73.5% of Group Revenue
Fosun Pharma, Yuyuan, Portuguese insurer Fidelidade, and the group's tourism segment together accounted for 73.5% of total revenue in the first half, the company disclosed. Pharmaceutical and insurance operations delivered the strongest performance among the four units.
Guo used the phrase "repairing the roof of our home on a sunny day" to describe efforts made over recent years to strengthen the group's foundation ahead of what he called a period of accelerated, steady growth.
Insurance-Industry Integration Set to Boost Future Profitability
Guo said Fosun has pursued integration between its insurance business and its competitive-advantage industries for more than three decades, calling it a strategic priority the group has now achieved. He said the move will strengthen industrial operating capabilities and enhance future profitability.
Wang Qunbin said Fosun continues to pursue business streamlining, aiming to gradually reach investment-grade credit rating status while concentrating capital on the insurance business and industries where it holds competitive advantages.
Technology Investment Rises 16.7% to RMB4.2 Billion
Fosun spent RMB4.2 billion on technology innovation in the first half, up 16.7% from a year earlier, with pharmaceuticals receiving the bulk of the funding. Chen Qiyu said the group has built research platforms spanning monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, fusion proteins, small molecules, autologous CAR-T, next-generation universal CAR-T and radiopharmaceuticals, with pipelines covering solid tumors, hematologic tumors, immunology and inflammation, neurodegenerative diseases, cardiovascular disease and metabolic disorders.
Chen said Chinese biopharmaceutical companies face a common obstacle after nearly two decades of R&D investment: building global commercialization capability. He said Fosun's response is to construct an integrated operating system spanning the value chain and roll out market-specific commercial strategies across China, the U.S. and emerging markets.
Xu Xiaoliang Outlines Four-Pillar Innovation Strategy
Xu described Fosun's innovation approach around four pillars — research and development, products, processes and scenarios — paired with a two-sided globalization plan. One side combines global R&D and manufacturing to create products and drive industrial synergy; the other builds global operations and marketing networks to expand brand reach and service coverage for customers worldwide.
CFO Points to Debt Reduction and Stable Credit Ratings
Gong Ping said operating revenue held steady with an improved mix, profitability rose and returned to a growth trajectory, and the group continued optimizing its asset portfolio while entering a valuation recovery phase. Gong said Fosun kept optimizing its balance sheet structure and reducing debt levels while maintaining stable credit ratings.
Guo told investors the half-year results, while well received, fall short of the group's ultimate goal, adding that the board's medium-term target of restoring annual profit to the RMB10 billion level is not the endpoint either. He said Fosun will keep focusing on industries where it holds competitive advantages to accelerate growth.